Tech Company Financing Transactions

Werewolf Therapeutics Funding Round

Longwood Fund, MPM Capital and Arkin Bio-Ventures participated in a $56 million Series A funding round for Werewolf Therapeutics. The round was recorded on 11/21/2019.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series A
Proceeds Purpose
The Series A financing will enable Werewolf to invest in research, talent acquisition and advancement of its platform and therapeutic programs to early clinical development.

Company Information

Company Status
Mailing Address
1030 Massachusetts Ave. 210
Cambridge, MA 02138
Email Address
A werewolf is a creature that can shape-shift, changing from its unassuming human form into a dangerous predator under specific conditions. Werewolf Therapeutics is developing medicines designed to be delivered systemically, but remain inactive in the body until they reach the tumor microenvironment, where they stimulate a powerful immune response.
Werewolf Therapeutics LinkedIn Company Profile
Social Media
Werewolf Therapeutics Company Twitter Account
Company News
Werewolf Therapeutics News
Werewolf Therapeutics on Facebook
Werewolf Therapeutics on YouTube

Management Team

Email & Social
Chief Executive Officer
Daniel Hicklin
  Daniel Hicklin LinkedIn Profile  Daniel Hicklin Twitter Account  Daniel Hicklin News  Daniel Hicklin on Facebook
Chief Financial Officer
David Cordo
  David Cordo LinkedIn Profile  David Cordo Twitter Account  David Cordo News  David Cordo on Facebook
Chief Operating Officer
Reid Leonard
  Reid Leonard LinkedIn Profile  Reid Leonard Twitter Account  Reid Leonard News  Reid Leonard on Facebook
Chief Scientific Officer
Cynthia Seidel-Dugan
  Cynthia Seidel-Dugan LinkedIn Profile  Cynthia Seidel-Dugan Twitter Account  Cynthia Seidel-Dugan News  Cynthia Seidel-Dugan on Facebook
Vice President
Andres Salmeron
  Andres Salmeron LinkedIn Profile  Andres Salmeron Twitter Account  Andres Salmeron News  Andres Salmeron on Facebook
Vice President
Philipp Steiner
  Philipp Steiner LinkedIn Profile  Philipp Steiner Twitter Account  Philipp Steiner News  Philipp Steiner on Facebook
VP - R & D
William Winston
  William Winston LinkedIn Profile  William Winston Twitter Account  William Winston News  William Winston on Facebook



Browse more venture capital transactions:

Prev: 11/21/2019: Proletariat venture capital transaction
Next: 11/21/2019: Superpedestrian venture capital transaction


Share this article


Where The Data Comes From

Our team works diligently to record every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data is sourced from, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary